Trial Profile
A Phase Ia Study to Assess the Safety and Immunogenicity of Novel Schedules for Vaccination With the Candidate Malaria Vaccines; AdCh63 AMA1, MVA AMA1 and AMA1-C1/Alhydrogel +/- CPG 7909
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Malaria vaccine (Primary) ; Agatolimod; Aluminium hydroxide
- Indications Malaria
- Focus Adverse reactions
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Aug 2012 Planned End Date changed from 1 Jan 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 22 Aug 2012 Planned End Date changed from 1 Jun 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.